BNP Paribas Financial Markets
KYTX icon

BNP Paribas Financial Markets’s Kyverna Therapeutics KYTX Stock Holding History

BNP Paribas Financial Markets’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.56M Buy
412,032
+159,881
+63% +$1.33M ﹤0.01% 2279
2025
Q4 		$2.37M Buy
252,151
+218,129
+641% +$1.62M ﹤0.01% 2515
2025
Q3 		$204K Buy
34,022
+29,591
+668% +$118K ﹤0.01% 4002
2025
Q2 		$13.6K Sell
4,431
-41,950
-90% -$104K ﹤0.01% 4757
2025
Q1 		$89.5K Buy
46,381
+1,398
+3% +$4.13K ﹤0.01% 4074
2024
Q4 		$168K Buy
44,983
+17,786
+65% +$85.2K ﹤0.01% 3956
2024
Q3 		$133K Buy
27,197
+25,997
+2,166% +$200K ﹤0.01% 3390
2024
Q2 		$9K Buy
+1,200
New +$18.3K ﹤0.01% 3729

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

BNP Paribas Financial Markets's KYTX Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Kyverna Therapeutics (KYTX) stake by 63% in Q1 2026, buying an estimated $1.33M and bringing the position to 412,032 shares worth $3.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2279.

BNP Paribas Financial Markets first reported a position in KYTX in Q2 2024 and has held it in 8 quarters since. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • BNP Paribas Financial Markets held 412,032 shares of Kyverna Therapeutics worth $3.56M as of Q1 2026.
  • BNP Paribas Financial Markets bought 159,881 Kyverna Therapeutics shares in Q1 2026, an estimated $1.33M.
  • Kyverna Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #2279 holding.
  • BNP Paribas Financial Markets first reported a position in Kyverna Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.